ページの先頭です
HOME > Past Issue List > Issue List > Abstract
言語を選択(Language)
日本語(Japanese)English

Abstract

Vol.74 No.6 November 2026

Two cases of pulmonary aspergillosis successfully treated with isavuconazole under careful tacrolimus therapeutic drug monitoring

Seishiro Arima1), Kazuya Miyagi1), Sayaka Imada1), Haruka Zukeyama1, 2), Mao Nishiyama1, 3), Wakako Arakaki1), Shuhei Ideguchi1), Hideta Nakamura1), Takeshi Kinjo1), Makoto Furugen1) and Kazuko Yamamoto1)

1)Division of Infectious, Respiratory, and Digestive Medicine, First Department of Internal Medicine, University of the Ryukyus Graduate School of Medicine, 1076 Kiyuna, Ginowan City, Okinawa, Japan
2)Division of Respiratory Disease and Internal Medicine, Northern Okinawa Medical Center
3)Division of Respiratory Disease and Internal Medicine, Nakagami Hospital

Abstract

Pulmonary aspergillosis is a refractory infection that requires long-term antifungal therapy. Use of azole antifungal agents is often challenging because of their inhibitory effects on cytochrome P450 3A4 (CYP3A4); however, isavuconazole (ISCZ) has weaker CYP3A4 inhibitory activity as compared with other azole antifungal agents. We report two cases of pulmonary aspergillosis that were treated with ISCZ that needed to be administered concomitantly with tacrolimus (TAC). Case 1 was a lung transplant recipient who developed chronic cavitary pulmonary aspergillosis while receiving immunosuppressive therapy and was initiated on oral voriconazole (VRCZ). However, as the patient developed visual disturbances and an increase of the TAC blood concentration from 4.8 to 8.1 ng/mL, the antifungal drug was switched to oral ISCZ. Following the switch, the TAC blood concentrations remained stable at 3.0-6.4 ng/mL, the ISCZ therapy could be continued and the patient's condition gradually improved. Case 2, a patient with an underlying invasive thymoma who was initiated on itraconazole (ITCZ) therapy for invasive pulmonary aspergillosis developed a marked increase of her TAC blood concentration, from 7.2 to 24.5 ng/mL; therefore, the antifungal drug was switched to oral ISCZ and the TAC dose was reduced. As subsequent monitoring showed stable TAC concentrations, the antifungal treatment was continued, and the lesion reduced in size. These two cases suggest that ISCZ can be used concomitantly with TAC under careful monitoring of the TAC blood concentrations. Few reports from Japan have described changes in TAC blood concentrations during concomitant use of TAC and ISCZ. Therefore, these cases serve to provide useful information when considering ISCZ treatment for pulmonary aspergillosis in patients receiving TAC.

Key word

isavuconazole, pulmonary aspergillosis, tacrolimus, therapeutic drug monitoring

Received

March 23, 2026

Accepted

July 7, 2026

Jpn. J. Chemother. 74 (6): 777-784, 2026